Add Formweb to your mobile device
Following is a P and T Committee update (from the July 28th meeting). Starting date for specific programs is 3 August 2015, unless otherwise noted. Please let me know if you have any questions or comments. Don’t forget to check the “New Drug Monitoring Spotlight” section of the website, which provides important monitoring information about newly approved drugs. Also, attached is the updated version of the “Not Stocked, Not Ordered” drug list with the new additions highlighted in red.
Below is the memo with links to the drug monographs, protocols, and formulary documents. Click to access the full P&T packet for this month, or here to access the P&T packet archive.
|
Drug or Drug Class |
Formulary Decision |
Comments |
|
Formulary status, restricted. |
Restricted to ICU/oncology related fever where other agents cannot be used. Also restricted to colo-rectal surgery cases. At this meeting, Ofirmev was approved for use by Drs. Kirby and Engle for use in their surgery cases involving the colon. |
|
|
Non-formulary, not stocked. |
Defer use to outpatient therapy. |
|
|
Non-formulary, not stocked. |
Defer use to outpatient therapy. |
|
|
Non-formulary, not stocked. |
Defer use to outpatient therapy. |
|
|
Non-formulary, not stocked. |
Natpara is supplied from a specialty pharmacy directly to the patient, and the hospital cannot order or keep a separate supply. There is a REMS program that requires specialty pharmacy and prescribing MD certification. Expensive and rare use expected. |
|
|
Non-formulary, not stocked, defer to outpatient use. |
This drug is similar to Invega Sustenna, but is administered once every 3 months. There is currently no voucher program. There are 4 strengths available, with cost ranging from about $2,000/ dose to about $5,500/ dose. |
|
|
Non-formulary, not stocked. |
This is a concentrated version of insulin glargine, which could cause confusion and lead to errors. Interchange to Lantus insulin on a 1 unit: 1 unit ratio. |
|
|
Non-formulary, not stocked. |
This is an older, rarely used sulfonylurea in which the stock is regularly going out of date. Will be deleted from stock. |
|
|
Restricted to uses other than postmenopausal osteoporosis or Paget’s disease |
Therapeutic interchange approved for postmenopausal osteoporosis and Paget’s disease. For injection doses of 100 intl units every other day or less, interchange to nasal spray. |
|
|
antipyrine-benzocaine otic (A/B Otic Sol.) Unapproved Prescription Otic Drops |
Non-formulary, not stocked. |
Removal of otic analgesics containing local anesthetics from formulary per FDA review. No alternative, FDA approved, analgesic ear drop is available at this time. |
|
Insulin Dose Rounding |
Approved to round DOWN to nearest whole unit if calculations result in dose in fractions |
Should help avoid medication errors and incidence of hypoglycemia. |
|
nalOXone PRN |
Expanded Pharmacy Use. |
Pharmacists may automatically add a PRN order for nalOXone to a patient’s medication profile if the patient has opiates ordered via any route or frequency, including PRN. |